Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions Signs an Option to Exclusive License Agreement with the University at Buffalo to Develop Novel Monoclonal Antibody Targeting a Multiligand Receptor Involved in Inflammatory Responses and Cancer

New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies […]

Published February 16, 2024

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

Published April 9, 2024

Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

Published June 1, 2018

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University